Ruey is the Founder & CEO of Advent Access Pte Ltd, a medical device startup pioneering innovations to preserve vascular access, improve quality of life and reduce overall cost of hemodialysis for kidney failure patients in Asia and across the world. Concurrently, Ruey is the Program Director of Singapore-Stanford Biodesign (SSB) - a medtech innovation joint venture between A*STAR, EDB and Stanford University, where Ruey holds executive responsibilities for the office.
Previously, Ruey was the Entrepreneur-In-Residence of the A*STAR Healthcare & Lifestyle (H&L) office and the Fellowship Head of SSB. As Entrepreneur-In-Residence of H&L, Ruey reviews and manages commercialization projects under the A*STAR-CIMIT collaboration, including leading a hospital-acquired infection technology through product development, clinical trial and its commercialization via spin-off company, HanGenix Inc. Ruey was also involved in the pioneering of the A*STAR BEP program and advised projects funded under the program in its early days. As Fellowship Head of SSB, Ruey was the head coach of the Asian phase of the Fellowship training. Ruey was further responsible for creating the SSB Class, the Asian version of the Stanford Biodesign Class, where Ruey teaches design-thinking principles for medtech to an audience of university students and industry professionals across Singapore.
With more than 12 years experience in medical device innovation, Ruey began his device career in the trenches of Silicon Valley startups, first as an R&D engineer with USGI Medical Inc, developing incisionless surgical devices for obesity and gastrointestinal diseases. Then as founding member, IP and R&D Manager of Voyage Medical Inc, developing advanced direct visualization and ablation catheter technologies for atrial fibrillation and other structural heart diseases.
Ruey is an inventor on > 45 issued and pending patents in cardiovascular, gastrointestinal and general surgery technologies. Ruey is the winner of both the Silicon Valley Boomers and the Stanford E-Challenge business plan competitions in 2009.
Ruey graduated from the National University of Singapore with a Bachelors in Mechanical Engineering (with Honors), a Minor in Technopreneurship and the NUS Achievement Award (Enterprise). He is also a graduate of Stanford University’s post-graduate Biodesign Fellowship where innovations he and his team developed led to 2 spin-off companies - Orpheus Medical and Pelvalon Inc.
Ruey was named MIT Technology Review’s “Top 10 Innovators under 35” of Asia Pacific in 2014; and Singapore’s “Top 50 Youths to Watch” by Straits Times in 2005.
Christopher Shen, MD is a Managing Director and head of U.S. healthcare investing at Vertex Management. Dr. Shen specializes in investments in biopharmaceutical and medical device companies. Previously, Dr. Shen worked at Essex Woodlands Health Ventures, a healthcare-focused venture capital and private equity firm. Prior to joining EWHV, he worked at New Enterprise Associates, one of the largest, diversified venture capital firms. Previously, Dr. Shen held the position of Senior Design Engineer at Guidant Corporation's Neurovascular Venture, an internal start-up, where he invented and commercialized a minimally-invasive therapy for the treatment of acute ischemic stroke. Dr. Shen also worked in Japan as a Design Engineer for Pfizer, Inc.’s Strategic Innovation Group, an internal medical technology incubator.
Dr. Shen is the U.S. Executive Director of the Singapore Stanford Biodesign Program and a Consulting Associate Professor of Medicine at Stanford University, focusing on medical technology innovation. He has nine patents issued and several pending in the fields of interventional neuroradiology and interventional cardiology.
Dr. Shen received his Doctor of Medicine from the Stanford School of Medicine, his Master of Business Administration from Stanford Graduate School of Business, and a Master of Biomechanical Engineering from the Stanford School of Engineering. He received his Bachelor of Science in Biological Sciences from Stanford University.
Dr. Uday N. Kumar, a cardiologist and cardiac electrophysiologist (EP) by training, is a serial entrepreneur whose interest lies in starting companies focused on creating solutions that lie at the convergence of value-driven engineering, information technology, user-centric design, and/or clinical service as these are themes that are increasingly important in today’s healthcare environment.
He is currently the Founder, President and CEO of Element Science, Inc., a venture-backed company funded by Third Rock Ventures and Google Ventures that is developing an innovative device for the treatment of sudden cardiac death. Prior to this, he was an Entrepreneur-in-Residence at Third Rock Ventures, where he focused on leading the development of new medical devices and technologies. Uday is also the Founder of iRhythm Technologies, Inc., a digital health company focused on developing cost-effective devices and systems for cardiac rhythm monitoring. He served as a Board member and Chief Medical Officer of iRhythm from founding through broad commercialization of its Zio® Patch cardiac monitoring device. Uday also Co-Founded and served as a Board Member of Sympara Medical, Inc. and Qurious.io, Inc.
Additionally, he currently serves as a Consulting Associate Professor of Bioengineering at Stanford University and is the Fellowship Director of Stanford’s Global Biodesign Programs (India and Singapore), programs that teach processes for medical innovation to solve unmet medical needs globally. Uday was a Biodesign fellow at Stanford, a cardiac EP and cardiology fellow at the University of California, San Francisco (UCSF), and internal medicine resident at the Columbia-Presbyterian Hospital of Columbia University. Prior to his training, Uday was Vice-President and Chief Medical Officer of Biomedical Modeling Inc., a start-up company that created rapid prototyping models from imaging data for use in numerous medical applications. Uday received his M.D. and B.A. (biochemistry and molecular biology) from Harvard University.
Ritu Kamal is the Director of Product Management at CellMax Life, an early stage startup commercializing novel cancer blood tests in Asia. She has previously worked at Roche Diagnostics as a Scientist. She was a 2010 Stanford India Biodesign Fellow, where she worked on developing new medical devices for better maternal and neonatal health. She has also been a Princeton-in-Africa Fellow, working in South Africa on prevention of HIV/AIDS from mothers to new-born children.
Ritu is the Assistant Director (US) for the Singapore Stanford Biodesign program. She is also part of the Stanford Biodesign faculty team supporting the new Japan Biodesign program.
She has a bachelors from Princeton University, MS from University of Pennsylvania and MBA from UC Berkeley.